Table 1.

Baseline clinical characteristics of the enrolled patients

Clinical characteristics	All patients (n = 106)	60 mg (n = 51)	80 mg (n = 55)
Age (years) (median [range])	64 [27–78]	64 [27–78]	63 [37–77]
Sex
Male	46 (43.4%)	22 (43.1%)	24 (43.6%)
Female	60 (56.6%)	29 (56.9%)	31 (56.4%)
ECOG PS
0	48 (45.3%)	20 (39.2%)	28 (50.9%)
1	58 (54.7%)	31 (60.8%)	27 (49.1%)
Smoking history
Current	10 (9.4%)	8 (15.7%)	2 (3.6%)
Former	26 (24.5%)	10 (19.6%)	16 (29.1%)
Never	67 (63.2%)	32 (62.7%)	35 (63.6%)
Unknown	3 (2.8%)	1 (2.0%)	2 (3.6%)
Disease stage
IIIB	7 (6.6%)	1 (2.0%)	6 (10.9%)
IIIC	1 (0.9%)	1 (2.0%)	0 (0%)
IV	98 (92.5%)	49 (96.1%)	49 (89.1%)
Baseline brain metastasis
Present	31 (29.2%)	16 (31.4%)	15 (27.3%)
Absent	74 (69.8%)	34 (66.7%)	40 (72.7%)
Unknown	1 (0.9%)	1 (2.0%)	0 (0%)
EGFR mutation status
EGFR exon 21 L858R	60 (56.6%)	26 (51.0%)	34 (61.8%)
EGFR exon 19 deletion	43 (40.6%)	23 (45.1%)	20 (36.4%)
Both	3 (2.8%)	2 (3.9%)	1 (1.8%)

ECOG PS Eastern Cooperative Oncology Group performance score